| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 77 | 14.0x | 17.8x | Top tier | |
Growth | 37 | 3.1% | 7.1% | Bottom tier | |
Quality | 93 | 16.0% | 4.5% | Top tier | |
Safety | 62 | 2.3x | 2.6x | Around median | |
Capital Return | 77 | 3.94% | 2.12% | Top tier | |
Momentum | 80 | 34.7% | 2.9% | Top tier | |
Sentiment | 46 | 17 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Bristol-Myers Squibb Company develops and markets specialized medicines, with a clear presence in oncology, hematology, cardiovascular disease, immunology, and neuroscience. Revenue depends on a growth portfolio that includes medicines such as Reblozyl, Breyanzi, Camzyos, Opdualag, Qvantig, Sotyktu, and Cobenfy, alongside a legacy portfolio led by Eliquis, Opdivo, and Revlimid. In Q2 of fiscal year 2026, the growth portfolio generated revenue of $7.6 billion, up 14%, and represented nearly 60% of total revenue, while 21% growth in Eliquis helped offset declines in legacy products affected by generic competition.
Revenue in Q2 of fiscal year 2026 reached approximately $13.0 billion, up 5% year over year, compared with $11.5 billion in Q1 of fiscal year 2026. According to EDGAR data, gross profit was $9.2 billion, net income was $3.3 billion, and earnings per share were $1.62, equivalent to a calculated gross margin of approximately 70.8%; meanwhile, the company reported an adjusted gross margin of 71.4% and adjusted diluted earnings per share of $2.04. For the twelve months ended in 2026, the company recorded revenue of $49.2 billion, gross profit of $34.5 billion, and net income of $9.3 billion, compared with revenue of $48.2 billion and net income of $7.1 billion in fiscal year 2025.
The analyst consensus is “Buy,” with an average price target of $69, a high of $75, and a low of $59. The average is slightly above the top of the 52-week range of $68.64, reflecting an expectation that growth in the new portfolio and the increase in fiscal year 2026 guidance can offset declines in legacy products. Conversely, the breadth of the targets at $59–$75 reveals uncertainty related to the $6.7 billion lawsuit, delays in some clinical readouts, and the loss of Eliquis exclusivity.
Figures in the text are as of 2026-08-27; the live price is shown at the top of the page.
Revenue increased 5% year over year to approximately $13.0 billion, while net income according to EDGAR reached approximately $3.3 billion and earnings per share were $1.62. The growth portfolio grew 14% to $7.6 billion, representing nearly 60% of revenue. Eliquis revenue also increased 21% to approximately $4.5 billion, helping offset declines in legacy products affected by generic competition.
On August 13, 2026, the FDA granted accelerated approval to ZENBEXUS, or mezigdomide, for the treatment of multiple myeloma as part of a combination regimen. According to the report, the medicine represents the first approved treatment in the CELMoD class and targets patients who experienced early relapse.
The growth portfolio generated $7.6 billion in revenue in Q2 of fiscal year 2026 and grew 14%, with ten products posting double-digit growth rates. Reblozyl rose 29%, Breyanzi 41%, and Camzyos 59%, while Qvantig revenue reached approximately $261 million. However, the legacy portfolio remains large, and management expects Eliquis revenue to decline by between $1.5 billion and $2.0 billion in fiscal year 2027, so the long-term offset has not yet been completed.
Automated analysis for informational purposes only — not investment advice.
The announced fiscal year 2026 readouts include admilparant in pulmonary fibrosis, iberdomide, RYZ101, and Sotyktu in lupus, in addition to programs in multiple myeloma. The milvexian atrial fibrillation readout moved to Q1 of fiscal year 2027, and the study requires 430 events for the primary stroke or embolism endpoint and 530 bleeding events before the database is locked. The company also expects ADEPT readouts for Cobenfy in Alzheimer's disease psychosis to begin during fiscal year 2027 and BALSAM readouts for bipolar disorder in the first half of fiscal year 2027.
On August 13, 2026, a U.S. appeals court revived a lawsuit seeking $6.7 billion related to allegations that approvals for three medicines were delayed to avoid payments to former Celgene shareholders. On August 25, 2026, the company terminated a $380 million manufacturing agreement with Cellares because it failed to meet the requirements for producing Breyanzi at commercial scale. In addition, execution risks are rising with delays to milvexian and the ADEPT programs, and with part of future growth depending on the success of clinical readouts whose results have not yet been released.
